Shree Pacetronix Ltd
Incorporated in 1988, Shree Pacetronix Ltd
is in the business of trading of Pacemakers.[1]
- Market Cap ₹ 64.8 Cr.
- Current Price ₹ 173
- High / Low ₹ 279 / 90.0
- Stock P/E 21.2
- Book Value ₹ 53.2
- Dividend Yield 0.00 %
- ROCE 23.7 %
- ROE 19.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 36.4%
- Company has high debtors of 180 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.89 | 7.44 | 6.94 | 6.80 | 7.28 | 8.77 | 7.56 | 9.23 | 20.26 | 22.04 | 16.68 | 21.62 | 20.74 | |
| Sales growth | -13.88% | +7.98% | -6.72% | -2.02% | +7.06% | +20.47% | -13.80% | +22.09% | +119.50% | +8.79% | -24.32% | +29.62% | +4.54% |
| 5.86 | 6.37 | 6.39 | 5.88 | 6.50 | 7.57 | 6.62 | 7.45 | 14.81 | 16.16 | 14.34 | 16.31 | 15.81 | |
| Operating Profit | 1.03 | 1.07 | 0.55 | 0.92 | 0.78 | 1.20 | 0.94 | 1.78 | 5.45 | 5.88 | 2.34 | 5.31 | 4.93 |
| OPM % | 14.95% | 14.38% | 7.93% | 13.53% | 10.71% | 13.68% | 12.43% | 19.28% | 26.90% | 26.68% | 14.03% | 24.56% | 23.77% |
| 0.03 | 0.02 | 0.05 | 0.01 | 0.17 | 0.04 | 0.05 | 0.07 | 0.10 | 0.14 | 0.12 | 0.12 | 0.15 | |
| Interest | 0.42 | 0.37 | 0.40 | 0.32 | 0.32 | 0.38 | 0.35 | 0.29 | 0.30 | 0.45 | 0.61 | 0.48 | 0.25 |
| Depreciation | 0.76 | 0.77 | 0.65 | 0.42 | 0.38 | 0.51 | 0.51 | 0.50 | 0.63 | 0.95 | 0.81 | 0.74 | 0.73 |
| Profit before tax | -0.12 | -0.05 | -0.45 | 0.19 | 0.25 | 0.35 | 0.13 | 1.06 | 4.62 | 4.62 | 1.04 | 4.21 | 4.10 |
| Tax % | -58.33% | 60.00% | -26.67% | 31.58% | 44.00% | 31.43% | 61.54% | 26.42% | 29.44% | 27.49% | 27.88% | 25.42% | |
| -0.06 | -0.09 | -0.32 | 0.13 | 0.14 | 0.24 | 0.05 | 0.78 | 3.26 | 3.36 | 0.75 | 3.14 | 3.05 | |
| EPS in Rs | -0.17 | -0.25 | -0.89 | 0.36 | 0.39 | 0.67 | 0.14 | 2.17 | 9.06 | 9.33 | 2.08 | 8.37 | 8.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 23% |
| 3 Years: | 2% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 43% |
| 5 Years: | 129% |
| 3 Years: | -1% |
| TTM: | 32% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 56% |
| 3 Years: | -17% |
| 1 Year: | -33% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 21% |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.60 | 3.75 | 3.75 |
| Reserves | 1.77 | 1.68 | 1.36 | 1.60 | 1.74 | 1.98 | 2.03 | 2.81 | 6.07 | 9.43 | 10.18 | 14.36 | 16.21 |
| 2.78 | 1.97 | 2.71 | 2.93 | 3.91 | 3.33 | 3.20 | 3.05 | 2.19 | 4.30 | 5.08 | 2.68 | 0.72 | |
| 0.95 | 1.35 | 1.16 | 1.33 | 1.35 | 2.08 | 2.15 | 2.72 | 4.68 | 4.42 | 4.19 | 4.92 | 5.40 | |
| Total Liabilities | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 23.05 | 25.71 | 26.08 |
| 3.13 | 2.55 | 2.02 | 1.88 | 2.40 | 2.47 | 2.69 | 2.56 | 3.12 | 4.24 | 3.87 | 3.81 | 4.20 | |
| CWIP | 0.00 | 0.00 | 0.77 | 0.99 | 1.25 | 1.81 | 1.64 | 1.65 | 1.66 | 0.93 | 0.93 | 0.93 | 1.09 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5.97 | 6.05 | 6.04 | 6.59 | 6.95 | 6.71 | 6.65 | 7.97 | 11.76 | 16.58 | 18.25 | 20.97 | 20.79 | |
| Total Assets | 9.10 | 8.60 | 8.83 | 9.46 | 10.60 | 10.99 | 10.98 | 12.18 | 16.54 | 21.75 | 23.05 | 25.71 | 26.08 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.47 | 1.35 | 0.42 | 1.13 | 0.31 | 2.25 | 1.09 | 1.76 | 1.69 | -0.04 | -0.01 | 2.92 | |
| -0.49 | -0.18 | -0.86 | -0.52 | -1.01 | -1.00 | -0.53 | -1.19 | -1.41 | -1.67 | -0.04 | -0.78 | |
| 0.20 | -1.14 | 0.22 | -0.50 | 0.36 | -1.17 | -0.31 | -0.45 | -1.10 | 1.75 | 0.19 | -1.61 | |
| Net Cash Flow | 0.18 | 0.03 | -0.22 | 0.10 | -0.34 | 0.08 | 0.25 | 0.12 | -0.82 | 0.04 | 0.14 | 0.54 |
| Free Cash Flow | -0.02 | 1.15 | -0.46 | 0.63 | -0.72 | 1.13 | 0.53 | 1.42 | 0.49 | -1.38 | -0.73 | 1.69 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 54% | 126% | 98% | 123% | 45% | 192% | 135% | 106% | 48% | 19% | 47% | 72% |
Ratios
Consolidated / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70.99 | 88.31 | 113.08 | 143.32 | 152.92 | 134.01 | 145.81 | 127.73 | 84.85 | 77.17 | 145.08 | 179.63 |
| Inventory Days | 670.58 | 359.32 | 243.33 | 301.93 | 276.44 | 216.62 | 272.02 | 194.20 | 157.41 | 285.83 | 463.17 | 275.46 |
| Days Payable | 29.71 | 32.67 | 18.86 | 49.65 | 37.10 | 54.15 | 48.57 | 17.55 | 32.22 | 12.45 | 57.32 | 60.45 |
| Cash Conversion Cycle | 711.86 | 414.96 | 337.55 | 395.60 | 392.26 | 296.48 | 369.25 | 304.38 | 210.04 | 350.55 | 550.93 | 394.64 |
| Working Capital Days | 107.01 | 116.27 | 110.97 | 107.35 | 100.27 | 42.87 | 37.66 | 23.33 | 63.06 | 101.68 | 157.77 | 180.31 |
| ROCE % | 3.56% | 4.16% | -0.80% | 6.46% | 5.06% | 7.93% | 5.30% | 14.43% | 46.15% | 34.74% | 9.12% | 23.66% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cumulative pacemaker implants count ・Standalone data |
|
||||||
| India revenue share (domestic vs export mix) % ・Standalone data |
|||||||
| Number of permanent employees count ・Standalone data |
|||||||
| R&D expenditure INR lakhs ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Kindly find enclosed herewith the extracts of Newspaper Publication Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015 of the Unaudited Standalone and Consolidated Financial …
-
Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (LODR) Regulations, 2015 For The Quarter And Half Year Ended 30Th September, 2026
- No deviation in preferential issue fund utilisation for quarter ended 30 September 2026; Rs.243.48 lakh raised.
-
Submission Of Unaudited Financial Results (Standalone And Consolidated) Along With Limited Review Report For The Quarter And Half Year Ended 30Th September, 2026.
- Shree Pacetronix reported Q2/H1 FY2026-27 results; standalone profit rose to Rs 111.12 lakh, with unmodified review.
-
Board Meeting Outcome for Outcome Of The (3Rd/2026-27) Board Meeting Held On Friday, 13Th November, 2026
- Board approved unaudited standalone and consolidated results for quarter and half-year ended 30 September 2026.
-
Board Meeting Intimation for Prior Intimation Of BM (3Rd/2026-2027) Of The Co Under Reg 29(1) And (2) Of SEBI (LODR) Reg 2015 To Inter-Alia, Consider And Approve The Standalone And Consolidated Unaudited FR For The Quarter And Half Year Ended 30.09.2026.
- Board meeting on 13 Nov 2026 to approve Q2 and half-year unaudited standalone and consolidated results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
SPL is in the business of delivering MRI safe life saving critical medical devices that regulate heart rhythms and improve the quality of life for patients suffering from cardiac conditions
such as arrhythmias and heart failure.